上海百心安生物技术股份有限公司宣布,其用于治疗高血压的Iberis肾动脉交感神经射频消融系统,已在越南成功完成产品注册。
这一进展标志着该创新医疗技术正式获准进入越南市场,为当地未控高血压患者提供了全新的介入治疗选择。公司表示,此次注册完成是其在亚太地区市场拓展的重要一步。
上海百心安生物技术股份有限公司宣布,其用于治疗高血压的Iberis肾动脉交感神经射频消融系统,已在越南成功完成产品注册。
这一进展标志着该创新医疗技术正式获准进入越南市场,为当地未控高血压患者提供了全新的介入治疗选择。公司表示,此次注册完成是其在亚太地区市场拓展的重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.